In the International Breast Cancer Study Group (IBCSG) Trials VII and 12-93, 893 postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable BC were randomized to receive either CHT or endocrine therapy or combined chemoendocrine treatment. This evidence concerns the gene ESR1 and breast cancer.